Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/2007
12/13/2007WO2007141806A1 Pharmaceutical formulations comprising oxcarbazepine and methods thereof
12/13/2007WO2007141764A1 Use of at least one polyphenol for promoting eye health
12/13/2007WO2007141743A2 A tablet dosage form comprising cetirizine and pseudoephedrine
12/13/2007WO2007141600A1 Current dependent nmda antagonists
12/13/2007WO2007141571A2 Aminothiazole derivatives as inhibitors of mark
12/13/2007WO2007141541A1 Intranasal administration
12/13/2007WO2007141538A1 Oxazole derivatives and their use in the treatment of diabetes and obesity
12/13/2007WO2007141533A2 Fkbp-l and uses thereof
12/13/2007WO2007141517A1 Benzimidazoles and their use for the treatemnt of diabetes
12/13/2007WO2007141513A1 Use of coumarin derivatives in antifungal therapy
12/13/2007WO2007141504A1 Fused thiophene derivatives as kinase inhibitors
12/13/2007WO2007141502A1 Chemical compounds
12/13/2007WO2007141491A1 Tricyclic oxazepines as in vivo imaging compounds
12/13/2007WO2007141473A1 N-(benzoyl)-o- [2- (pyridin- 2 -ylamino) ethyl] -l-tyrosine derivatives and related compounds as a5b1 antagonists for the treatment of solid tumors
12/13/2007WO2007141423A1 Ppar enhancing derivatives, method for preparing same and therapeutic use thereof
12/13/2007WO2007141413A1 Use of a cannabinoid cb1 receptor antagonist for preparation of drugs useful for the prevention and treatment of benign prostatic hypertrophy
12/13/2007WO2007141392A2 Compositions comprising betulonic acid
12/13/2007WO2007141391A1 Betulin derived compounds useful as antiprotozoal agents
12/13/2007WO2007141390A1 Betulin derived compounds useful as antiviral agents
12/13/2007WO2007141389A1 Betulin derived compounds useful as antibacterial agents
12/13/2007WO2007141352A1 Functional food composition that is rich in phenolic compounds and use of said composition
12/13/2007WO2007141351A1 Food composition for functional foods and nutritional supplements
12/13/2007WO2007141343A1 Phenyl pyrrole aminoguanidine derivatives
12/13/2007WO2007141328A1 Low dose sublingual tablets of opioid analgesics and preparation process
12/13/2007WO2007141318A1 2,5-disubstituted piperidines
12/13/2007WO2007141315A1 Improved method of treatment of bacterial infections
12/13/2007WO2007141308A1 Process for preparing spray dried formulations of tmc125
12/13/2007WO2007141298A1 Stabilized pharmaceutical compositions comprising fesoterodine
12/13/2007WO2007141285A1 Treatment of gastrointestinal disorders with cgrp-antagonists
12/13/2007WO2007141284A2 Treatment of gastrointestinal disorders with cgrp antagonists
12/13/2007WO2007141283A2 Salts and crystalline salt forms of an 2-indolinone derivative
12/13/2007WO2007141269A1 Novel receptor antagonists and their methods of use
12/13/2007WO2007141267A1 N- (phenylmethyl) -2- (1h-pyraz0l-4-yl) acetamide derivatives as p2x7 antagonists for the treatment of pain, inflammation and neurodegeneration
12/13/2007WO2007141253A1 Process for the production of intermediates for the preparation of tricyclic imidazopyridines
12/13/2007WO2007141224A2 Jnk inhibitors for treatment of skin diseases
12/13/2007WO2007141200A1 Novel n-aryl and n-heteroaryl substituted pyridinone derivatives for use in mch-1 mediated diseases
12/13/2007WO2007141141A1 O/w emulsion for caring for hands
12/13/2007WO2007141026A1 Use of a polyphenol in the treatment of the metabolic syndrome and endothelial dysfunction or other vascular sequellae.
12/13/2007WO2007141018A1 Therapeutic combination for painful medical conditions
12/13/2007WO2007141002A1 Co-crystals of pyrrolidinones
12/13/2007WO2007140987A1 Stable and bioavailable formulations and a novel form of desloratadine
12/13/2007WO2007140982A1 Substituted benzoxazoles
12/13/2007WO2007140980A1 Pyrrolidine derivatives useful as bace inhibitors
12/13/2007WO2007140957A1 Sulfimides as protein kinase inhibitors
12/13/2007WO2007140934A1 Substituted 4-aryl-1,4-dihydro-1,6-naphthyridines and use thereof
12/13/2007WO2007140924A1 Use of vascular endothelial growth factor receptor inhibitors for the treatment of cancer
12/13/2007WO2007140894A1 5-aryl-substituted dihydropyridopyrimidines and dihydropyridazines and use thereof as mineral corticoid antagonists
12/13/2007WO2007140791A1 Treatment of cutaneous neurogenic inflammation
12/13/2007WO2007140786A1 Use of cannabinoid receptor agonists as hypothermia inducing drugs for the treatment of ischemia
12/13/2007WO2007140681A1 The use of cucurbitacins or cucurbitacin compositions in preparation of medicaments for raising leukocytes
12/13/2007WO2007140662A1 Fluoroalkyloxy-containing combretastatin derivatives, preparation and use thereof
12/13/2007WO2007140614A1 Nasal formulation
12/13/2007WO2007140611A1 Salts of trimebutine and n-desmethyl trimebutine
12/13/2007WO2007140590A1 Methods and compositions for inducing bone synthesis
12/13/2007WO2007140555A1 Pharmaceutical composition comprising cyclobenzaprine and aceclofenac in association
12/13/2007WO2007140551A2 Treatment of cnidaria intoxication with vanilloid receptor antagonists
12/13/2007WO2007140521A1 Manufacture of bagasse powder
12/13/2007WO2007130364A3 Compositions, methods, and kits for treating dry eye
12/13/2007WO2007127763A3 Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
12/13/2007WO2007124092A3 Photoacid generator compounds and compositions
12/13/2007WO2007121546A8 Use of mas-g-protein-coupled receptor agonists in the treatment of the metabolic syndrome, its components and its complications
12/13/2007WO2007120827A3 Use of biarylcarboxamides in the treatment of hedgehog pathway-related disorders
12/13/2007WO2007119001A3 Aminomethyl pyridine derivatives, method for preparing same and therapeutic use thereof
12/13/2007WO2007117982A3 Organic compounds
12/13/2007WO2007117981A3 Selective hydroxamate based mmp inhibitors
12/13/2007WO2007117923A3 Compositions including relatively water insoluble/unwettable drugs and methods for using same
12/13/2007WO2007116428A8 Oral pharmaceutical composition containing cystine or cysteine with glutathione against oxidative stress resulting from haemodialysis
12/13/2007WO2007116025A3 Use of c-src inhibitors in combination with a pyrimidylaminobenzamide compound for the treatment of leukemia
12/13/2007WO2007113575A3 Reagents and methods for cross-linking biological molecules
12/13/2007WO2007111904A3 C-met protein kinase inhibitors for the treatment of proliferative disorders
12/13/2007WO2007110811A3 Use of the staudinger ligation in in vivo assembly of a biologically active compound
12/13/2007WO2007110730A3 Varenicline standards and impurity controls
12/13/2007WO2007110152A8 Polylactide nanoparticles
12/13/2007WO2007109251A3 Tumor necrosis factor alpha inhibitors and their use in the treatment of human diseases
12/13/2007WO2007107291A3 Agents for influencing receptors and consequences thereof
12/13/2007WO2007105154A3 Antibiotic compounds
12/13/2007WO2007103776A3 A2a adenosine receptor antagonists
12/13/2007WO2007103529A3 Antisense antiviral compound and method for treating arenavirus infection
12/13/2007WO2007103295A3 Halogenated sulfonamide derivatives
12/13/2007WO2007101247A3 Compositions and methods to treat diseases characterized by cellular proliferation and angiogenesis
12/13/2007WO2007101060A3 Compounds for the treatment of metabolic disorders
12/13/2007WO2007098183A3 Treatment of cancer with 2-deoxygalactose
12/13/2007WO2007097980A3 Ubiquitin/proteasome inhibitors for the treatment of spinal muscular atrophy
12/13/2007WO2007097871A3 Piperazine derivatives
12/13/2007WO2007095174A3 Bile acid derivatives as fxr ligands for the prevention or treatment of fxr-mediated diseases or conditions
12/13/2007WO2007093635A3 Proteasom or ups inhibitor for treating infections with influenza viruses
12/13/2007WO2007093409A3 Mcp-i binding nucleic acids
12/13/2007WO2007092729A3 Compounds for the treatment of metabolic disorders
12/13/2007WO2007090882A3 Pharmaceutical extended release compositions comprising pramipexole
12/13/2007WO2007090553B1 Compounds useful as agonists of a2a adenosine receptors, cosmetic compositions with a2a agonists and a method for using the same
12/13/2007WO2007089743A3 Potassium channel inhibitors
12/13/2007WO2007087505A3 Compounds for the treatment of metabolic disorders
12/13/2007WO2007087344A3 Anti-histamine compositions and use thereof
12/13/2007WO2007087188A3 Taste-masked tablets and granules
12/13/2007WO2007087130A3 Hydroxyalkylarylamide derivatives
12/13/2007WO2007084815A3 Substituted thienopyrimidine kinase inhibitors
12/13/2007WO2007084625A3 Novel compounds and methods for inhibiting p53 activity
12/13/2007WO2007081995A3 Urotensin ii receptor antagonists
12/13/2007WO2007081980A3 Methods and compositions for treating prostate cancer
12/13/2007WO2007081560A3 Amino acid derivatives of indolinone based protein kinase inhibitors
1 ... 3459 3460 3461 3462 3463 3464 3465 3466 3467 3468 3469 3470 3471 3472 3473 3474 3475 3476 3477 3478 3479 ... 7860